Home > Research > Publications & Outputs > Considerations on covariates and endpoints in m...
View graph of relations

Considerations on covariates and endpoints in multi-arm multi-stage clinical trials selecting all promising treatments

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Published

Standard

Considerations on covariates and endpoints in multi-arm multi-stage clinical trials selecting all promising treatments. / Jaki, Thomas; Magirr, Dominic.
In: Statistics in Medicine, Vol. 32, No. 7, 30.03.2013, p. 1150-1163.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Harvard

APA

Vancouver

Jaki T, Magirr D. Considerations on covariates and endpoints in multi-arm multi-stage clinical trials selecting all promising treatments. Statistics in Medicine. 2013 Mar 30;32(7):1150-1163. Epub 2012 Nov 1. doi: 10.1002/sim.5669

Author

Jaki, Thomas ; Magirr, Dominic. / Considerations on covariates and endpoints in multi-arm multi-stage clinical trials selecting all promising treatments. In: Statistics in Medicine. 2013 ; Vol. 32, No. 7. pp. 1150-1163.

Bibtex

@article{7f9cb2a97e6d4dfdb99d267c3ff9954a,
title = "Considerations on covariates and endpoints in multi-arm multi-stage clinical trials selecting all promising treatments",
abstract = "In early stages of drug development, there is often uncertainty about the most promising among a set of different treatments. To ensure the best use of resources in such situations, it is important to decide which, if any, of the treatments should be taken forward for further testing. In later development, it has been shown that evaluating more than one dose increases the chance of success substantially. In this work, we discuss how multi-arm multi-stage trials can be designed such that all promising treatments are kept in the study at the interim analyses. We first investigate the impact of deviating from the planned design and show how confidence intervals can be constructed before we consider the impact of important covariates. We show that under orthogonality, the inclusion of covariates has no effect on familywise error rate control in the strong sense. We further show that the derived methodology can be used to investigate non-normal endpoints.",
keywords = "confidence intervals, Dunnett test, multi-arm, multi-stage, ordinal, time-to-event",
author = "Thomas Jaki and Dominic Magirr",
year = "2013",
month = mar,
day = "30",
doi = "10.1002/sim.5669",
language = "English",
volume = "32",
pages = "1150--1163",
journal = "Statistics in Medicine",
issn = "0277-6715",
publisher = "John Wiley and Sons Ltd",
number = "7",

}

RIS

TY - JOUR

T1 - Considerations on covariates and endpoints in multi-arm multi-stage clinical trials selecting all promising treatments

AU - Jaki, Thomas

AU - Magirr, Dominic

PY - 2013/3/30

Y1 - 2013/3/30

N2 - In early stages of drug development, there is often uncertainty about the most promising among a set of different treatments. To ensure the best use of resources in such situations, it is important to decide which, if any, of the treatments should be taken forward for further testing. In later development, it has been shown that evaluating more than one dose increases the chance of success substantially. In this work, we discuss how multi-arm multi-stage trials can be designed such that all promising treatments are kept in the study at the interim analyses. We first investigate the impact of deviating from the planned design and show how confidence intervals can be constructed before we consider the impact of important covariates. We show that under orthogonality, the inclusion of covariates has no effect on familywise error rate control in the strong sense. We further show that the derived methodology can be used to investigate non-normal endpoints.

AB - In early stages of drug development, there is often uncertainty about the most promising among a set of different treatments. To ensure the best use of resources in such situations, it is important to decide which, if any, of the treatments should be taken forward for further testing. In later development, it has been shown that evaluating more than one dose increases the chance of success substantially. In this work, we discuss how multi-arm multi-stage trials can be designed such that all promising treatments are kept in the study at the interim analyses. We first investigate the impact of deviating from the planned design and show how confidence intervals can be constructed before we consider the impact of important covariates. We show that under orthogonality, the inclusion of covariates has no effect on familywise error rate control in the strong sense. We further show that the derived methodology can be used to investigate non-normal endpoints.

KW - confidence intervals

KW - Dunnett test

KW - multi-arm, multi-stage

KW - ordinal

KW - time-to-event

U2 - 10.1002/sim.5669

DO - 10.1002/sim.5669

M3 - Journal article

VL - 32

SP - 1150

EP - 1163

JO - Statistics in Medicine

JF - Statistics in Medicine

SN - 0277-6715

IS - 7

ER -